The Defense Security Cooperation Agency notified Congress [link opens in PDF] Thursday of plans to conduct a Foreign Military Sale of $170 million worth of equipment and support services to Finland, as part of that country's Finland's F-18 Mid-Life Upgrade Program.
According to the DSCA, contractors including Raytheon (NYSE: RTN ) , Lockheed Martin (NYSE: LMT ) , Boeing (NYSE: BA ) , General Electric (NYSE: GE ) , and General Dynamics (NYSE: GD ) will participate in providing the requested services, as well as equipment to include:
69 KIV-78 friend-or-foe identification systems. 69 AN/APX-11-30 combined interrogator/transponders. 32 SUU-63 payload pylons. An unspecified number of Multifunctional Information Distribution Systems.Also included in the proposed order will be software test and integration center upgrades, flight testing services, support and testing equipment, technical documentation, personnel training, and assorted spare parts.
Hot Warren Buffett Companies To Own For 2015: Bank of Ireland (BKIR)
Bank of Ireland and its subsidiaries provide a range of banking and other financial services. The Company operates in five segments: Retail Ireland, Bank of Ireland Life, Retail UK, Corporate and Treasury and Group Centre. Group Centre includes capital management activities, unallocated Group support costs and the cost of the Credit Institutions. Retail Ireland distributes a range of financial products and services through the Bank�� branch operations in the Republic of Ireland and through its direct channels. The Company operates in the life and pensions market in Ireland through its wholly owned subsidiary New Ireland Assurance Company plc (NAIC).Retail UK consists of Business Banking in Great Britain and Northern Ireland, the branch network in Northern Ireland, the United Kingdom residential mortgage business and the business activities with the United Kingdom Post Office. Corporate and Treasury division consists of Corporate Banking, Global Markets and IBI Corporate Finance. Advisors' Opinion:- [By Sarah Jones]
In Dublin, Bank of Ireland (BKIR) slipped 3.4 percent to 14.1 euro cents and Permanent TSB Group Holdings Plc (IPM) tumbled 13 percent to 2.6 cents. Allied Irish Banks Plc (ALBK), which is owned by the state, slid 1.5 percent to 6.5 cents.
10 Best Stocks To Invest In Right Now: Eaton Vance Senior Floating-Rate Trust (EFR)
Eaton Vance Senior Floating-Rate Trust (the Fund) is a closed-end management investment company. The Fund�� investment objective is to provide a high level of current income and preservation of capital by investing primarily in senior, secured floating rate loans (Senior Loans). Eaton Vance Senior Floating-Rate Trust invests in various industries, including healthcare, publishing, cable and satellite television, chemicals and plastics, and business equipment and services.
The Fund invests at least 80% of its total assets in Senior Loans. The Fund may also invest in second lien loans and high yield bonds. Eaton Vance Management serves as the investment advisor of the Fund.
Advisors' Opinion:- [By John Dowdee]
The following 10 funds satisfied all of these conditions:
BlackRock Float Rate Strategies (FRA). This CEF sells at a discount of 3%, which is low compared to an average premium of 2% over the past year. The distribution has been managed at 6.1% and a small amount (less than 10%) has been return of capital (ROC). However, this has not negatively affected net asset value (NAV) so has not been destructive. The fund holds 447 securities, with 90% in floating rate loans. FRA utilizes 27% leverage and has an expense ratio of 1.7%, including interest payments. Eaton Vance Floating Rate (EFR). This CEF sells at a 1% premium, which is low compared to an average premium of 5% over the past year. The distribution is 6.2%, none of which was ROC. The fund holds 800 securities, with 90% in floating rate loans. About 85% of the securities are from U.S. companies. EFR utilizes 35% leverage and has an expense ratio of 1.8% including interest payments. ING Prime Rate Trust (PPR). This CEF sells for a premium of 2%, which is below the average premium of 5%. It has a distribution of 6.8%, none of which was ROC. The fund has 350 holdings, virtually all in senior loans and from US companies. PPR utilizes 29% leverage and has a high expense ratio of 2.1%, including interest payments. Invesco VK Dynamic Credit Opportunities (VTA). This CEF sells for a discount of 5%, which is below the average discount of 1%. It has a distribution of 7.1%, none of which was ROC. The fund has 495 holdings, with 76% in floating rate loans. About 25% of the loans are from non-US companies. VTA utilizes a relatively low 20% leverage but still has a high expense ratio of 2.1%, including interest payments. Invesco VK Senior Income (VVR). This CEF sells for a discount of 1%, which is below the average premium of 3%. It has a distribution of 7.1%, none of which was ROC. The fund has over 500 holdings, with 89% in floating rate loans. Almost all (95%) securities are from US companies. VVR ut
10 Best Stocks To Invest In Right Now: USmart Mobile Device Inc (UMDI)
USmart Mobile Device Inc., formerly ACL Semiconductors Inc., incorporated on September 17, 2002, the Company is engaged primarily in the business of distributing memory products under the Samsung brand name, which consists of Dynamic Random Access Memory (DRAM), Graphic Random Access Memory (Graphic RAM) and Flash for the Hong Kong and Southern China markets. The primary products the Company distributes and sells include Synchronous Dynamic Random Access Memory (SDRAMs), DDRs (DDR1, DDR2 and DDR3), Flash memory, Graphic RAM and LCD panels. In September 2012, the Company acquired Jussey Investments Limited.
Synchronous Dynamic Random Access Memory (SDRAMs), or mobile SDRAM, are used semiconductor memory component in computer peripherals, such as Hard Disk Drives (HDD), Digital Still Camera (DSC), Modems, ADSL Applications, DVD player, Set-top Box (STB), Digital TV, High Definition TV (HDTV) and Portable Multimedia Players (PMP). DDRs (DDR1, DDR2 and DDR3) are random access memory components that transfer data on both 0-1 and 1-0 clock transitions, theoretically yielding twice the data transfer rate of normal RAM or SDRAM.
Flash memory is a specialized type of memory component used to store user data and program code; it retains this information even when the power is off. Although Flash is predominantly used in mobile phones and tablets, it is commonly used in multi-media digital storage applications for products, such as moving picture experts group layer-3 audio (MP3) players, digital still camera DSC, Digital Voice Recorders, universal serial bus (USB) Disks and Flash Cards. Graphic RAM is a special purpose DDR (GDDR1, GDDR2, GDDR3, GDDR4) that is used in graphic products which require high-speed 3-dimensional calculation performance and a memory size to be used as data storage buffer for digital versatile disc (DVD) and computer game displays. LCD panels are a component in consumer electronics, such as LCD TVs, tablets, smartphones, notebooks, digital phone frames and por! table game consoles.
The Company competes with Toshiba, Hynix, Nanya, PSC, Promos, ISSI and ESMT.
Advisors' Opinion:- [By Peter Graham]
Last Friday, small cap stocks MedCAREERS Group Inc (OTCMKTS: MCGI), USmart Mobile Device Inc (OTCMKTS: UMDI) and Drinks Americas Holdings, Ltd (OTCMKTS: DKAM) were all over the place with the first two sinking 54% and 48.05%, respectively, while the last one rose 10.81%. It should be mentioned that all three small cap stocks have been the subject of paid promotions albeit none of these stocks have been over promoted. So where can investors and traders expect these stocks to head this week? Here is a quick look at what you might expect:
10 Best Stocks To Invest In Right Now: Rudolph Technologies Inc.(RTEC)
Rudolph Technologies, Inc. designs, develops, manufactures, and sells process control defect inspection, metrology, and process control software systems to microelectronics device manufacturers. The company provides yield management solutions for use in wafer processing and final manufacturing through a range of standalone systems for macro-defect inspection, test systems, and transparent and opaque thin film measurements. It also offers a range of process control software solutions for semiconductor, solar, and LED manufacturing. It provides products for various applications in the areas of macro-defect detection and classification, diffusion, etch, lithography, CVD, PVD, and CMP. The company sells its products and solutions to logic, memory, data storage, and application-specific integrated circuit device manufacturers. It sells its products in the United States, Taiwan, China, Singapore, South Korea, Japan, and Europe. The company was founded in 1940 and is based in Fla nders, New Jersey.
Advisors' Opinion:- [By John Emerson]
In case you are wondering, I only made peanuts on what should have been a monumental success. You see I never sold a share of Camtek until the autumn of 2008. I exchanged them for shares in their arch rivals Orbitech (OBRK) and Rudolph (RTEC) which had become large net/net propositions (more on those purchases of ORBK and RTEC later in the series).
- [By Ben Axler]
In the table below, we've listed a sample of small-cap semiconductor capital equipment stocks such as Entegris (ENTG), Advanced Energy Industries (AEIS), ATMI Inc. (ATMI), MKS Instruments (MKSI), Photronics Inc. (PLAB), Rudolph Technologies (RTEC),FormFactor (FORM) and Mattson Technology (MTSN). The peers trade at approximately 1.0x and 15.5x 2014E revenues and EPS, respectively. Furthermore, the average peer trades at 2.1x tangible book value. However, these multiples are based on average 2014E industry revenue and earnings growth of 18% and 119%, respectively. Axcelis is poised to grow at a rate substantially above the industry average.
- [By Seth Jayson]
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Rudolph Technologies (Nasdaq: RTEC ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Rudolph Technologies doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue increased 17.6%, and inventory increased 32.2%. Comparing the latest quarter to the prior-year quarter, the story looks potentially problematic. Revenue dropped 8.9%, and inventory grew 32.2%. Over the sequential quarterly period, the trend looks worrisome. Revenue dropped 23.3%, and inventory grew 10.8%. - [By Seth Jayson]
When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Rudolph Technologies (Nasdaq: RTEC ) .
10 Best Stocks To Invest In Right Now: Galena Biopharma Inc (GALE)
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).
The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.
In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.
The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.
The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.
Advisors' Opinion:- [By James E. Brumley]
The last two weeks have been absolutely fantastic ones for Galena Biopharma Inc. (NASDAQ:GALE). Shares have soared from $2.37 to the current price of $3.32 - a 40% pop - rewarding investors who had been patiently waiting through late October for the runup to take hold. Congratulations if that's you. But, if that was you, then now might be a great time to take the money and run with the trade, as GALE looks poised to make a sizeable pullback. More on that in a moment.
10 Best Stocks To Invest In Right Now: Solazyme Inc (SZYM)
Solazyme, Inc. (Solazyme), incorporated on March 31, 2003, makes oil. The Company�� technology transforms a range of plant-based sugars into oils. Its renewable products can replace or enhance oils derived from the world�� three existing sources-petroleum, plants and animal fats. The Company is focused on commercializing its products into three target markets: fuels and chemicals, nutrition, and skin and personal care. In 2010, the Company launched its products, the Golden Chlorella line of dietary supplements. In March 2011, the Company launched its Algenist brand for the luxury skin care market through marketing and distribution arrangements with Sephora S.A. (Sephora International), Sephora USA, Inc. (Sephora USA), and QVC, Inc. (QVC).
The Company is engaged in development activities with multiple partners, including Chevron U.S.A. Inc., through its division Chevron Technology Ventures (Chevron), The Dow Chemical Company (Dow), Ecopetrol S.A. (Ecopetrol), Qantas Airways Limited (Qantas) and Conopoco, Inc., doing business as Unilever (Unilever).
In 2010, the Company entered into a 50/50 joint venture with Roquette Freres, S.A. (Roquette). In November 2010, the Company entered into a joint venture and operating agreement for Solazyme Roquette Nutritionals with Roquette. In December 2010, the Company entered into an exclusive distribution relationship with Sephora International, and in January 2011, the Company entered into a distribution relationship with Sephora USA. Under the arrangements, each of Sephora International and Sephora USA will distribute the Algenist product line in their respective territories.
In Fuels and Chemicals market its renewable oils can be refined and sold as drop-in replacements for marine, motor vehicle and jet fuels, as well as replacements for chemicals that are traditionally derived from petroleum or other conventional oils. The Company work with its refining partner Honeywell UOP to produce Soladiesel (renewable diesel), So! ladiesel renewable diesel for United States Naval vessels, and Solajet renewable jet fuel for both military and commercial application testing. In nutrition market the Company has developed microalgae-based food ingredients, including oils and powders that enhance the nutritional profile and functionality of food products while reducing costs for consumer packaged goods (CPG) companies. In Skin and Personal Care market the Company hs developed a portfolio of branded microalgae-based products. Its ingredient is Alguronic Acid, which the Company has formulated into a range of skin care products with anti-aging benefits. The Company is also developing algal oils as replacements for the oils used in skin and personal care products.
The Company competes with BP p.l.c., Royal Dutch Shell plc, and Exxon Mobil Corporation, jatropha, camelina, SALOV North America Corporation, Archer Daniels Midland Company, Cargill, Incorporated, DSM Food Specialties and Danisco A/S
Advisors' Opinion:- [By Maxx Chatsko]
You call it cheating -- I call it looking ahead
Who said biotech investments are confined to health care and pharmaceuticals? Solazyme (NASDAQ: SZYM ) has nothing to do with either, but forward-thinking investors won't let that stop them. The industrial biotechnology company is developing a novel renewable oils platform that could one day produce commercial quantities of in-spec chemicals for a variety of applications including cosmetics, flavors and fragrances, specialty chemicals, and fuels. - [By Dan Caplinger]
ADM has sought to grow by reaching out to industry peers. It allowed Solazyme (NASDAQ: SZYM ) to use an Iowa plant to produce its renewable algal oils, which helped Solazyme boost its overall production to achieve commercial-scale levels. Meanwhile, ADM's ongoing attempt to buy the remaining 80% of Australia's GrainCorp that it doesn't already own has met with resistance, as the Australian exporter has so far rebuffed a sweetened bid for the company. Whether those moves will pay off for ADM in the long run remains to be seen.
- [By Maxx Chatsko]
Acknowledge the future
When thinking about biotechnology I like to encourage investors to take a big-picture approach that goes beyond pharma. Dozens of industrial biotech companies will produce commercial quantities of chemicals, fuels, fragrances, personal-care products, nutritionals, and more by the end of the decade. Two of the more promising investments currently within reach of investors are Solazyme (NASDAQ: SZYM ) and Amyris (NASDAQ: AMRS )
10 Best Stocks To Invest In Right Now: Powershares Qqq Trust Series 1 (QQQ)
PowerShares QQQ Trust, Series 1, formerly The NASDAQ-100 Trust, Series 1, is a unit investment trust that issues securities called Nasdaq-100 Index Tracking Stock. The Trust holds all of the component securities of the Nasdaq-100 Index. The Trust's investment objective is to provide investment results that generally correspond to the price and yield performance of the Nasdaq-100 Index.
The Trust was created to provide investors with the opportunity to purchase units of beneficial interest in the Trust representing proportionate undivided interests in the portfolio of securities held by the Trust, which consists of substantially all of the securities, in substantially the same weighting, as the component securities of the Nasdaq-100 Index. Nasdaq Global Funds, Inc. is the sponsor of the Trust and The Bank of New York is the trustee of the Trust.
Advisors' Opinion:- [By Dan Caplinger]
2. Technology
The Technology Select Sector SPDR (NYSEMKT: XLK ) weighs in with $10 billion in assets. It's much less popular among traders, with only 11 million shares trading on an average day. That's likely because the alternative Nasdaq-100 tracking PowerShares QQQ (NASDAQ: QQQ ) is the favored ETF for tech exposure, as the Nasdaq includes most of the largest tech stocks in the market.
No comments:
Post a Comment